Kit Roes | Professor
Radboudumc

Kit Roes is Professor of Biostatistics at Radboud University Medical Center Nijmegen (Netherlands). He is chair of the Methodology Working Party of the European Medicines Agency, and senior expert at the Dutch Medicines Evaluation Board. His research focus is design and analysis of clinical trials in the context of regulatory science, with an emphasis on innovative designs, rare diseases and bridging the gap between clinical trials and real world evidence. His experience includes over 25 years in clinical research in the pharmaceutical industry and academic life sciences, serving clinical research and drug development as expert as well as in different (international) senior management positions.

Appearances:

Pre-Congress Workshops - Monday 27th October @ 14:00

Public Private Partnerships in Rare Disease: Ideas to action

This workshop will explore innovative approaches to cross-sector partnerships in the EU rare disease landscape. Participants will examine successful case studies that highlight innovative collaborations in rare disease research and diagnostics, showcasing how diverse stakeholders can work together to overcome challenges. The session will highlight partnerships that have demonstrated significant impact across the European rare disease ecosystem. By fostering knowledge exchange and promoting innovative strategies, this workshop aims to inspire and equip attendees with actionable insights to enhance multi-sector collaboration and ultimately improve outcomes for rare disease patients across Europe.

Interdisciplinary Collaboration: Tools and Insights for Successful Rare Disease Partnerships
IHI RealiseD - compRehensive mEthodological Approach to cLinical trIalS in (ultra-)rarE Diseases
Newborn Screening in the EU: Historical Perspectives and Future Horizons

Moderator: Anne-Sophie Chalandon, Head of Global Public Affairs, Rare Diseases and CGT Policies, SANOFI

Mathieu Boudes, Senior Advisor, FIPRA

Vinciane Pirard, Medical - SAI, Sanofi

Alicia Granados, Head, Global Rare Diseases Medical Scientific Advocacy, Sanofi